New gel could heal painful finger sores in rare disease
NCT ID NCT06954597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called TOP-N53, applied directly to finger ulcers in people with systemic sclerosis (scleroderma). The main goal is to check safety and see if it improves pain and blood flow. Fifteen participants will receive either the drug or a placebo over up to 31 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TOP-N53 (a nitric oxide-releasing drug applied to the skin)
- What this could lead to
- If it works, this could point toward a new topical treatment to help heal finger ulcers and reduce pain in people with scleroderma.
- What could go wrong
- This is a very early, small trial with only 15 people, so results may not apply to everyone. The drug is applied directly to open wounds, which carries a risk of irritation or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGITAL ULCERS IN SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP Hôpital Cochin
RECRUITINGParis, 75014, France
-
CHRU Lille, Hôpital Claude Huriez, Rue Michel Polonosvski
RECRUITINGLille, 59000, France
-
CHU Grenoble Alpes
RECRUITINGLa Tronche, 38 700, France
-
Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie
RECRUITINGBordeaux, 33000, France
-
Reha Rheinfelden, Salinenstrasse 98
RECRUITINGRheinfelden, Canton of Aargau, 4310, Switzerland
-
Universitätsspital Zürich, Klinik für Rheumatologie, Rämistrasse 100
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland